Latest Biotech News

Beacon Biosignals secured $86 million in funding to assemble a large, standardized EEG dataset aimed at powering diagnostics and drug development in neurology and psychiatry. The company will...

Evotec announced a milestone payment after Bristol Myers Squibb accepted an IND derived from their strategic protein‑degradation alliance. The $5 million milestone reflects progress in a...

Gene‑editing heavyweight Metagenomi cut roughly 25% of its workforce — including the CEO — as it refocuses on a preclinical hemophilia A program, the company said in a corporate restructuring...

The FDA sketched a new regulatory approach—the “plausible mechanism” pathway—intended to accelerate approvals for individualized and ultra-rare therapies. Agency officials and authors published...

Novartis reported Phase 3 results showing its combination therapy GanLum (ganaplacide plus lumefantrine) was non-inferior to standard of care in 1,688 patients across sub-Saharan African sites and...

The FDA appointed longtime oncology chief Richard Pazdur as director of the Center for Drug Evaluation and Research, a move the agency framed as stabilizing amid recent leadership turnover....

Gene-editing company Metagenomi announced a workforce reduction of roughly 25% and leadership departures, including its CEO, as the firm reorients toward a preclinical hemophilia A program. The...

Nilo Therapeutics launched with a $101 million Series A to develop therapies that modulate neural circuits to restore immune homeostasis. The New York-based company, founded by neuroscientists and...

Beacon Biosignals closed an $86 million financing to assemble a large brain‑wave dataset intended to accelerate drug and diagnostic development for neurological disorders. The company plans to...

Two preclinical studies identified actionable nodes to amplify cancer immunotherapy. One report showed that loss of the E3 ligase TRIM25 enhances T-cell anti‑tumor activity through modulation of...

Mayo Clinic researchers unveiled a predictive model that estimates Alzheimer’s risk years before clinical symptoms using decades of clinic data; the model appears to stratify individuals for...

Engene/EnGene disclosed additional pivotal‑cohort data for its nonviral gene therapy detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in...

Researchers at Stanford published evidence connecting Epstein‑Barr virus infection to the development of systemic lupus erythematosus. The study demonstrated that EBV can reprogram B cells to...

Novartis reported Phase 3 results showing GanLum (ganaplacide + lumefantrine) achieved non‑inferiority to current standard therapy and cleared World Health Organization efficacy thresholds in...

The FDA named Richard Pazdur to lead the Center for Drug Evaluation and Research (CDER), moving its long‑time oncology chief into the agency’s top drug regulator role. Pazdur’s appointment follows...

Top FDA officials and agency commentators outlined a new regulatory roadmap—often called the “plausible‑mechanism” pathway—intended to accelerate approvals for bespoke, patient‑specific therapies....

Analyses indicate GLP‑1 receptor agonists are shifting from specialty to mass‑market drugs. Medicare policy changes and potential coverage expansions are expected to reduce patient prices while...

The CRISPR sector faced contrasting developments: Intellia reported a fatality and an FDA clinical‑hold risk in its MAGNITUDE Phase III program after a patient developed severe liver injury,...

Nilo Therapeutics launched with a $101 million Series A to translate neuro‑immunology discoveries into therapies that modulate brain‑body circuits to restore immune homeostasis. Backers include...

Multiple preclinical studies strengthened VISTA’s candidacy as an immune‑checkpoint target. One paper shows that loss of TRIM25 enhances anti‑tumor immunity by modulating VISTA pathways in T...